期刊文献+

甾体5α-还原酶抑制剂的研究进展 被引量:8

Progress in research of steroidal 5α-reductase inhibitors
下载PDF
导出
摘要 前列腺组织内双氢睾酮含量的升高引起良性前列腺增生症 ,而双氢睾酮是通过 5α 还原酶转化睾酮而得 ,因此抑制 5α 还原酶的活性即可达到治疗良性前列腺增生症的目的。本文综述了甾体 5α 还原酶抑制剂的分类。 Benign prostatic hyperplasia(BPH) is resulted from the growth of dihydrotestosterone in the prostate. Studies have demonstrated that human steroidal 5α reductase responsible for the conversion of testosterone into dihydrotestosterone. Thus inhibition of steroidal 5α reductase could offer an alternative therapy for BPH.The classfication,structure activity relationship,and progression in research of 5α reductase inhibitors were reviewed.
作者 蒋晟 廖清江
出处 《中国新药杂志》 CAS CSCD 2000年第7期438-442,共5页 Chinese Journal of New Drugs
关键词 甾体5α-还原酶抑制剂 构效关系 BPH benign prostatic hyperplasia(BPH) steroidal 5α reductase inhibitors structure activity relationship research progress
  • 相关文献

参考文献15

  • 1 Thigpen AE,Silver RI, Graul A.Tissue distribution and ontogeny of steroid 5α-reductase expression[J].JClin Invest,1993,92(3)∶903~910
  • 2 Levy MA, Brandt M, Greway AT. Mechanistic studies with solubilized rat liversteroid 5α-reductase: eluciodation of the kinetic mechanism[J].Biochemistry,1990,29(11)∶2808 [3] Levy MA, Brandt M, Richard H,et al. Inhibition of rat liver steroid 5α-reductaseby 3-androstene-3-carboxylic acids: Mechanism of enzyme inhibitor interaction[J].Biochemistry,1990,29(11)∶2814~2815
  • 3 Kenny B, Miller AM, Williamson JR,et al. Pharmacological options in thetreatment of benign prostatic hyperplasia[J].J Med Chem,1997,40(9)∶1293~1315
  • 4 Baskshi RK, Patel GF, Rasumusson GH, et al.4,7β-dimethyl-4-azachlolestan-3-one(MK-386)and related 4-azasteroids as selective inhibitors of human type Ⅰ5α-reductase [J].JMed Chem, 1994,37(23)∶3871~3874
  • 5 Salle ED, Pazeri A. Testosterone 5α-reductase inhibitor[J].DrugsFut,1993,18(5)∶436~439
  • 6 Finasteride[J].Annu Drug Data Rep,1992,14(10)∶996~999
  • 7 Mcclellan KJ. Finasteride: a review of its use in male pattern hair loss [J].Drugs,1999,57(1)∶111~126
  • 8 Graul A, Silvestre J, Castaner J,et al. Dutasteride, steroid 5α-reductaseinhibitor, treatment of BPH[J].Drugs Fut,1999,24(3)∶246~253
  • 9 Frye SV, Haffner CD, Maloney PR, et al.6-azasteroids:potent dual inhibitor ofhuman type 1 and type 2 steroid 5α-reductase[J].J Med Chem, 1993,36(26)∶4313~4315
  • 10 Frye SV, Haffner CD, Maloney PR,et al. Structure-activity relationship forinhibition of type 1 and 2 human 5α-reductase and human adrenal 3β-hydroxy-Δ5-steroiddehydrogenase /3-keto-Δ5-steroid isomerase by6-azaandrost-4-en-3-ones:optimization of the C17 substituent[J].J MedChem,1993,36(26)∶4313~4315

同被引文献44

  • 1陈德云,杨军.特拉唑嗪治疗老年前列腺增生的临床研究[J].医学信息(医学与计算机应用),2000,13(5):280-280. 被引量:2
  • 2崔毓桂,张桂元.正常成年男性5a-还原酶活性的测定[J].生殖医学杂志,1995,4(1):11-15. 被引量:9
  • 3吕坚伟,周立新,冷静,黄翼然,唐涌志,汤海,闵志廉,高轶.萘哌地尔与盐酸特拉唑嗪治疗良性前列腺增生的疗效与安全性评估[J].中国男科学杂志,2005,19(5):36-39. 被引量:20
  • 4赵兴梅,朱敏,杨明,陶科,王锦秀.蜣螂抗实验性前列腺增生作用研究[J].中药药理与临床,2006,22(5):37-38. 被引量:23
  • 5[1]Culley Carson,Roger Rittmaster. The role of dihydrotestosterone in benign prostatic hyperplasia[J] Urology ,2003,61 (Supplement 4A):120.
  • 6[3]Alka Kurup,Rajni Garg,Corwin Hansch. Comparative QSAR analysis of 5α-reductase inhibitors[J]. Chem Rev, 2000,100(3):909.
  • 7[6]Bernard Faller, David Farley, Hanspeter Nick. Finasteride:A slow-binding 5α-Reductase Enzyme Inhibitors[J]. Biochemistry,1993,32 (21):5707.
  • 8[7]Audet PR, BaineNH,Benincosa LJ,et al.Epristeride steroid 5α-reductase inhibitor treatment for benign prostatic hyperplasia[J]. Drugs Fut,1994,19(7):646.
  • 9[8]Stephen V F,Curt D H,Patrick R M, et al. Structure-activity relationships for inhibition of type 1 and 2 human 5α-Reductase[J]. J Med Chem, 1994, 37(15):2352.
  • 10[9]Barry Kenny,Stephen Ballard,Julian Blagg,et al. Pharmacological options in the treatment of benign prostatic hyperplasia[J]. J Med Chem, 1997,40(9):1293.

引证文献8

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部